In addition, siramesine combined with lapatinib promotes the death of BC cells by increasing reactive oxygen species (ROS) through iron transport disruption, independent of downstream targets (members of the EGFR family) and cathepsin B, which suggests that the other targets of siramesine and lapatinib are associated with ferroptosis and provides hope for overcoming apoptotic resistance in BC (16). The gene discussed is CTSB; the disease is breast cancer.